Sandoz Archives | Page 3 of 3

Home / Posts tagged Sandoz (Page 3)

Sandoz Inaugurates New Antibiotic Production Plant in Austria and New Biosimilar Development Center in Germany

Investment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicines New penicillin production process will significantly improve ecological footprint and help secure European-based supply Cutting-edge development hub will play key role in supporting long-term growth of leading biosimilar business Basel, November 10, 2023 (Korea Bizwire) – Sandoz, the global leader in generic [...]

Sandoz Successfully Issues EUR 2.0 Billion Inaugural Eurobonds

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN Inaugural Eurobonds priced earlier today; three tranches of EUR 700 million, EUR 700 million and EUR 600 million Maturities of 3.5, 6.5 and 10 years, carrying fixed coupons at 3.97%, 4.22% and 4.50%, respectively Proceeds to repay bridge loan facility and for [...]

Sandoz Successfully Issues CHF 750 Million in Inaugural Bonds

Highly successful inaugural CHF senior bonds priced earlier today Two tranches of CHF 400 million and CHF 350 million with maturities of 3 and 8 years, carrying 2.125% and 2.600% fixed coupons, respectively Proceeds to partially repay bridge loan facility and for general corporate purposes Basel, October 26, 2023 (Korea Bizwire) – Sandoz, the global leader [...]

Sandoz Reports Year-to-date Sales for the First Nine Months of 2023

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Nine-month net sales1 of USD 7.1 billion, up 6 percent in constant currencies (cc)(1) Solid performance in Generics; Biosimilars grow double-digits Recent strategic milestones include US Hyrimoz® launch, approval of Tyruko® in US and Europe, partnership on ustekinumab and closing of Mycamine® acquisition Full-year 2023 guidance confirmed [...]

Sandoz Enters New Era as Standalone Global Leader and European Champion in Generic and Biosimilar Medicines

Spin-off from Novartis successfully completed with first trading day today on SIX Swiss Exchange; Sandoz shares included in key market indices Standalone Sandoz committed to extend leadership in stable and growing market via purpose-driven strategy with focus on sustainable access Differentiating investment grade credit profile and six strategic levers to drive long-term value Basel, October [...]